Skip to content

RxSight, Inc. RXST Proceeds from maturities of short-term investments

Proceeds from maturities of short-term investments at other companies

Air Products and Chemicals logo
Air Products and ChemicalsAPD
$0-100%
Clover Health Investments logo
Clover Health InvestmentsCLOV
$2.86M-88.9%
BILL Holdings logo
BILL HoldingsBILL
$465.88M-25.4%
Definitive Healthcare Corp. logo
Definitive Healthcare Corp.DH
-$9.48M+90.8%
Flywire Corporation logo
Flywire CorporationFLYW
$11.27M-88.6%
Fabrinet logo
FabrinetFN
$112.11M+180%

Other financials

Income statement

See full
Revenue$30.9M-18.5%
Gross profit$23.5M-17.1%
Operating income-$17.8M-67.0%
Net income-$15.9M-93.9%
EPS (diluted)-$0.38-90.0%

Balance sheet

See full
Cash & equivalents$17.6M-37.2%
Total debt$10.8M-10.1%
Total equity$267.3M-4.3%
Total assets$304.0M-2.9%

Cash flow

See full
Operating cash flow-$10.9M-23.3%
CapEx$759.0K+32.0%
Free cash flow-$11.7M-23.8%

Valuation

See full
Market cap$232.23M-56.8%
Enterprise value$225.49M-55.7%
P/S1.8×-1.8×

Profitability

See full
Gross margin77%+5.1pp
Operating margin-43.4%+128pp
Net margin-36.6%-867pp
FCF margin-16.9%+4.9pp

Returns & leverage

See full
Return on equity-17.1%+12.6pp
Debt / equity0.0×
Current ratio10.2×-2.5×

Where this comes from

Reported directly by RxSight, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.

The official record: RxSight, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about RxSight, Inc.'s proceeds from maturities of short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RxSight, Inc.'s proceeds from maturities of short-term investments?
RxSight, Inc. (RXST) reported proceeds from maturities of short-term investments of $110M in Q1 2026.
How has RxSight, Inc.'s proceeds from maturities of short-term investments changed year-over-year?
RxSight, Inc.'s proceeds from maturities of short-term investments increased by 83.3% year-over-year, from $60M to $110M.
What is the long-term trend for RxSight, Inc.'s proceeds from maturities of short-term investments?
Over 4 years (2021 to 2025), RxSight, Inc.'s proceeds from maturities of short-term investments has grown at a 34.3% compound annual growth rate (CAGR), from $80M to $260M.